Live tape
Top 8, mentions 7d10,066TSLA2,067 mentions▲ +0.05GOOGL1,609 mentions▲ +0.04NVDA1,230 mentions▲ +0.07CRWV1,216 mentions▲ +0.03SPCX1,103 mentions▲ +0.07QQQ1,076 mentions▲ +0.04META891 mentions▲ +0.05NBIS874 mentions▲ +0.06

Equity · Healthcare

ANAB

NASDAQ

AnaptysBio, Inc.

$46.58 −4.27% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 16, 2026
Price · Chart
63 sessions
$65 $45 21 Jul 16 Oct

The line runs $54 on 21 July through $46.58 on 16 October, on a scale from $45 to $65. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 63 sessions, 21 Jul – 16 Oct 2026
Market cap $1.4B
52-week range $31 – $70
Avg volume 36.2K

as of Oct 16, 2026

ANAB insider trades

SEC Form 4 · last 90 days · newest reported trade 1 Oct 2026
Open-market buys 0
Open-market sells 1
Net sold $249K
Non-trade filings 2
Date Insider Type Shares Value
01 Oct 2026 RENTON HOLLINGS Director Sell 5,000 $249K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Oct 2026 RENTON HOLLINGS Director Option exercise 5,000 $90K
15 Sep 2026 Orwin John A Director Option exercise 1,300

ANAB reported financials

SEC EDGAR XBRL SEC EDGAR

ANAB reported revenue of $234.6M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$13.2M.

Figure Reported Period
Revenue $234.6M 31 Dec 2025 fiscal year
Net income −$13.2M 31 Dec 2025 fiscal year
Diluted EPS −$0.46 31 Dec 2025 fiscal year
Total assets $329.7M 31 Mar 2026 at period end
Total equity $12.7M 31 Mar 2026 at period end

ANAB earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 FY 2026 $3.50 $53M
31 Mar 2026 Q1 2026 −$1.84 $26M
31 Dec 2025 FY 2025 −$0.44 $235M
30 Sep 2025 Q3 2025 $0.52 $76M
30 Jun 2025 FY 2026 −$2.54 $50M
31 Mar 2025 Q1 2025 −$1.28 $28M
31 Dec 2024 FY 2024 −$4.92 $91M
30 Sep 2024 Q3 2024 −$1.14 $30M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ANAB institutional holders

SEC Form 13F SEC EDGAR

8 of the 45 institutional funds we track reported a ANAB position for the quarter ended 30 Jun 2026 — a combined $146.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Millennium Management Added +69.8% shares 807,316 $54.5M
D. E. Shaw & Co. Held (±25%) −6.8% shares 539,666 $36.4M
Citadel Advisors Added +68.9% shares 394,373 $26.6M
Two Sigma Investments Trimmed −43.5% shares 262,995 $17.8M
Renaissance Technologies Trimmed −35.9% shares 58,300 $3.9M
AQR Capital Management Added +42.7% shares 46,323 $3.1M
Marshall Wace Trimmed −35.6% shares 43,822 $3.0M
Tudor Investment Corp Added +303.4% shares 20,019 $1.4M
Balyasny Asset Management Exited
Fisher Asset Management Exited

ANAB fails-to-deliver

SEC CNS data SEC

On 25 Sep 2026, 751 shares of ANAB failed to deliver (about $39K).

Settlement date Shares failed Notional % of shares out
25 Sep 2026 751 $39K 0.003%
04 Sep 2026 9 $517 <0.001%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 31 Mar 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings